AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17237853 — intervention group
Group type: COMPARATOR
Intervention: Only radiotherapy to a total dose of 60 Gy in conventional fractionation (Group C)
Number of subjects: 60
Study 14616430 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort extract (300 mg, twice daily)
Number of subjects: 18
Study 14616430 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort extract (300 mg, three times daily)
Number of subjects: 18
Study 14616430 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral contraceptive alone (control)
Number of subjects: 18
Study 10749463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone for 4 days (4 injections)
Number of subjects: 100
Study 10749463 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone for 7 days
Number of subjects: 100
Study 8932983 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interleukin‐6 (rhIL‐6) at doses of 1, 3 or 10 micrograms/kg/day for 7 consecutive days
Number of subjects: 12
Study 8932983 — intervention group
Group type: COMPARATOR
Intervention: cyclophosphamide/G‐CSF
Number of subjects: 12
Study 1573785 — intervention group
Group type: EXPERIMENTAL
Intervention: SPG group (radiotherapy + SPG)
Number of subjects: 292
Study 1573785 — intervention group
Group type: COMPARATOR
Intervention: Control group (radiotherapy only)
Number of subjects: 292
Study 3931145 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg b.i.d. for 7 days
Number of subjects: 18
Study 3931145 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg b.i.d. for 7 days
Number of subjects: 18
Study 30997619 — intervention group
Group type: COMPARATOR
Intervention: Medical Weight Loss (MWL)
Number of subjects: 15
Study 30997619 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable Gastric Banding (AGB)
Number of subjects: 15
Study 30997619 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 15
Study 30997619 — intervention group
Group type: EXPERIMENTAL
Intervention: AGB
Number of subjects: 15
Study 28667715 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered care intervention using an audio-video tool on personal hygiene, hand washing, danger signs recognition, and feeding of sick neonate.
Number of subjects: 295
Study 28667715 — intervention group
Group type: COMPARATOR
Intervention: Routine care by nurses and doctors (Control group).
Number of subjects: 295
Study 25046337 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 75 mg
Number of subjects: 319
Study 25046337 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 150 mg
Number of subjects: 319
Study 25046337 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 319
Study 25046337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 24039365 — intervention group
Group type: COMPARATOR
Intervention: PPI (lansoprazole 30 mg/d orally)
Number of subjects: 90
Study 24039365 — intervention group
Group type: EXPERIMENTAL
Intervention: rebamipide (300 mg orally, three times a day)
Number of subjects: 90
Study 21768463 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib (ET) - erlotinib (150 mg daily) and tivantinib (360 mg twice daily)
Number of subjects: 167
Study 21768463 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus placebo (EP) - erlotinib (150 mg daily) and placebo
Number of subjects: 167
Study 21768463 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib (ET)
Number of subjects: 167
Study 21768463 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus placebo (EP)
Number of subjects: 167
Study 21768463 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib (ET) for patients with KRAS mutations
Number of subjects: 167
Study 21768463 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus placebo (EP) with crossover to ET
Number of subjects: 167
Study 21768463 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib (ET) and Erlotinib plus placebo (EP)
Number of subjects: 167
Study 19805683 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose casopitant (150 mg PO on day 1)
Number of subjects: 0
Study 19805683 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day oral casopitant (150 mg PO on day 1 plus 50 mg PO on days 2 to 3)
Number of subjects: 0
Study 19805683 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day IV/oral casopitant (90 mg IV on day 1 plus 50 mg PO on days 2 to 3)
Number of subjects: 0
Study 19805683 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 17078124 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment for treatment trial
Number of subjects: 0
Study 17078124 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants assessed for the study
Number of subjects: 0
Study 17078124 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualified participants who chose not to join
Number of subjects: 0
Study 15499522 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CRVO
Number of subjects: 236
Study 15499522 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with venous thrombosis
Number of subjects: 236
Study 15499522 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 236
Study 12477521 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial culture medium formulation
Number of subjects: 208
Study 12477521 — intervention group
Group type: COMPARATOR
Intervention: Control culture medium formulation
Number of subjects: 208
Study 9717115 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheterization using a hysteroscopic catheter (3-French diameter tapering to 2 French at the tip)
Number of subjects: 20
Study 9717115 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-catheterized tubes)
Number of subjects: 20
Study 9717115 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheterization using a hysteroscopic catheter
Number of subjects: 20
Study 7983951 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 225
Study 7983951 — intervention group
Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 225
Study 3278115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound localization
Number of subjects: 116
Study 3278115 — intervention group
Group type: COMPARATOR
Intervention: Less than 10 needle manoeuvres
Number of subjects: 116
Study 3278115 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 10 needle manoeuvres
Number of subjects: 116
Study 28983556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab, 0.5 mg, and verteporfin photodynamic therapy (vPDT)
Number of subjects: 322
Study 28983556 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab, 0.5 mg, and sham PDT
Number of subjects: 322
Study 26154207 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kg backpack
Number of subjects: 8
Study 23803562 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristbands (pressing the P6 point)
Number of subjects: 500
Study 23803562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupressure wristbands
Number of subjects: 500
Study 23803562 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 500
Study 23803562 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristbands (both real and sham)
Number of subjects: 500
Study 23803562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of acupressure
Number of subjects: 500
Study 23803562 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender effect on nausea response
Number of subjects: 500
Study 20653397 — intervention group
Group type: EXPERIMENTAL
Intervention: Diascorea alata (12 mg/sachet, 2 sachets daily for 12 months)
Number of subjects: 50
Study 20653397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19755462 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circuits (Mini‐CPB)
Number of subjects: 40
Study 19755462 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circuits (CECC)
Number of subjects: 40
Study 16438813 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor received risk communication training alone
Number of subjects: 584
Study 16438813 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor received SDM training alone
Number of subjects: 584
Study 16438813 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor received both risk communication and SDM training
Number of subjects: 584
Study 16438813 — intervention group
Group type: COMPARATOR
Intervention: Doctor received no training
Number of subjects: 584
Study 15310009 — intervention group
Group type: EXPERIMENTAL
Intervention: AR CAG instability in BPH patients
Number of subjects: 84
Study 15310009 — intervention group
Group type: COMPARATOR
Intervention: AR CAG and GGN repeat size
Number of subjects: 84
Study 11545541 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0
Study 11545541 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/leucovorin
Number of subjects: 0
Study 11545541 — intervention group
Group type: COMPARATOR
Intervention: Mayo Clinic regimen
Number of subjects: 0
Study 9154286 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (0.35, 115, and 350 micrograms/ml) administered topically to both eyes after a baseline day with vehicle (placebo).
Number of subjects: 23
Study 9154286 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (10 times the clinically recommended dose for glaucoma treatment).
Number of subjects: 23
Study 9154286 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) administered to asthmatic patients on baseline day.
Number of subjects: 23
Study 8330470 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide (10 mg orally and intravenously)
Number of subjects: 12
Study 8330470 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide (10 mg)
Number of subjects: 12
Study 3298087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 100
Study 3298087 — intervention group
Group type: COMPARATOR
Intervention: Combination antibiotic therapy
Number of subjects: 100
Study 29243965 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib monotherapy
Number of subjects: 0
Study 26712605 — intervention group
Group type: EXPERIMENTAL
Intervention: ContEx (40 min of brisk walking 40 min after lunch)
Number of subjects: 9
Study 26712605 — intervention group
Group type: EXPERIMENTAL
Intervention: SplitEx (two 20‐min isoenergetic bouts, before and 40 min after meal)
Number of subjects: 9
Study 26712605 — intervention group
Group type: COMPARATOR
Intervention: Control (standard lunch followed by normal daily activities)
Number of subjects: 9
Study 25405014 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-core biopsy protocol
Number of subjects: 354
Study 25405014 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-core biopsy protocol
Number of subjects: 354
Study 25405014 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-core biopsy protocol
Number of subjects: 354
Study 25405014 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 10-core, 12-core, and 16-core protocols
Number of subjects: 354
Study 23274402 — intervention group
Group type: EXPERIMENTAL
Intervention: Kin Keeper(SM) Cancer Prevention Intervention (treatment group)
Number of subjects: 514
Study 23274402 — intervention group
Group type: COMPARATOR
Intervention: Participant client group (control group)
Number of subjects: 514
Study 19686327 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aloe vera (AV)
Number of subjects: 80
Study 19686327 — intervention group
Group type: COMPARATOR
Intervention: 0.1% triamcinolone acetonide (TA)
Number of subjects: 80
Study 18400727 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 mug Se as sodium selenite/d) for 6 weeks
Number of subjects: 0
Study 18400727 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium withdrawal after supplementation
Number of subjects: 0
Study 18400727 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-protein binding assays
Number of subjects: 0
Study 16760808 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteromedial approach
Number of subjects: 31
Study 16760808 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral approach
Number of subjects: 31
Study 15223865 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 49
Study 15223865 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1
Number of subjects: 49
Study 15223865 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF
Number of subjects: 49
Study 11178853 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarin/troxerutine
Number of subjects: 48
Study 11178853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9266098 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Conserving Therapy (BCT)
Number of subjects: 187
Study 9266098 — intervention group
Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 187
Study 8318241 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms IV over 30 minutes and an additional 150 micrograms during the following 90 minutes
Number of subjects: 60
Study 8318241 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride IV at identical time intervals
Number of subjects: 60
Study 8318241 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine infusion
Number of subjects: 60
Study 3704666 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy alone
Number of subjects: 432
Study 3704666 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 432
Study 3704666 — intervention group
Group type: EXPERIMENTAL
Intervention: 32P
Number of subjects: 432
Study 3704666 — intervention group
Group type: COMPARATOR
Intervention: Control group (phlebotomy)
Number of subjects: 432
Study 31972249 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06700841 30 mg (n = 14)
Number of subjects: 30
Study 31972249 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06700841 100 mg (n = 7)
Number of subjects: 30
Study 31972249 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06700841 (both dosages)
Number of subjects: 30
Study 31972249 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 30
Study 30907230 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 0
Study 30907230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27390168 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Number of subjects: 0
Study 27390168 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 0
Study 27390168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27390168 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept exposure (quartiles)
Number of subjects: 0
Study 27390168 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of BLyS and APRIL
Number of subjects: 0
Study 27390168 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection rates
Number of subjects: 0
Study 25850386 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed educational material
Number of subjects: 564
Study 25850386 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing to primary care physicians
Number of subjects: 564
Study 25850386 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing plus tailored telephone education
Number of subjects: 564
Study 23391760 — intervention group
Group type: EXPERIMENTAL
Intervention: MWM‐with‐Tape
Number of subjects: 25
Study 23391760 — intervention group
Group type: COMPARATOR
Intervention: MWM
Number of subjects: 25
Study 21410557 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional restorative treatment
Number of subjects: 244
Study 21410557 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 244
Study 21410557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraconservative treatment
Number of subjects: 244
Study 21410557 — intervention group
Group type: COMPARATOR
Intervention: Control group (children receiving local anaesthesia)
Number of subjects: 244
Study 19597879 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin responsiveness in stabilized IE patients
Number of subjects: 16
Study 19597879 — intervention group
Group type: COMPARATOR
Intervention: Control group (48 patients without systemic infection)
Number of subjects: 16
Study 19597879 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antithrombin III activity
Number of subjects: 16
Study 19597879 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative fibrinogen level
Number of subjects: 16
Study 19597879 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin resistance
Number of subjects: 16
Study 18057479 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 120
Study 18057479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15041603 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 68
Study 15041603 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 68
Study 15041603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 68
Study 15041603 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 68
Study 11339485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat Free Mass (FFM)
Number of subjects: 10
Study 11339485 — intervention group
Group type: COMPARATOR
Intervention: Total Body Mass (TBM)
Number of subjects: 10
Study 9218071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg nocte
Number of subjects: 42
Study 9218071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8432920 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UVB (Philips TL 01)
Number of subjects: 23
Study 8432920 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UVB (Philips TL 01) with dithranol
Number of subjects: 23
Study 8432920 — intervention group
Group type: COMPARATOR
Intervention: Conventional broad-band UVB (Sylvania UV 6)
Number of subjects: 23
Study 2979684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (average dose 10 mg)
Number of subjects: 101
Study 2979684 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam in lipid emulsion (average dose 18.4 mg)
Number of subjects: 101
Study 30759357 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment-based manual therapy
Number of subjects: 72
Study 30759357 — intervention group
Group type: COMPARATOR
Intervention: Sham manual therapy (control)
Number of subjects: 72
Study 28281738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg daily from 30 min before and up to 3 days after procedure)
Number of subjects: 128
Study 28281738 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravenous hydration only)
Number of subjects: 128
Study 28281738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 128
Study 26674626 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFNα‐2a combined with ribavirin for 48 weeks
Number of subjects: 125
Study 26674626 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFNα‐2a combined with ribavirin for 72 weeks
Number of subjects: 125
Study 26674626 — intervention group
Group type: COMPARATOR
Intervention: Previously treated with interferon alone
Number of subjects: 125
Study 26674626 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously treated with interferon plus ribavirin
Number of subjects: 125
Study 26674626 — intervention group
Group type: COMPARATOR
Intervention: Previously treated with common interferon (c‐IFN)
Number of subjects: 125
Study 26674626 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously treated with Peg‐IFN
Number of subjects: 125
Study 26674626 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid virological response (RVR)
Number of subjects: 125
Study 26674626 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete early virological response
Number of subjects: 125
Study 26674626 — intervention group
Group type: EXPERIMENTAL
Intervention: RVR, early virological response, delayed virological response
Number of subjects: 125
Study 26674626 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 125
Study 23483064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium 2 g/12 h and intravenous human albumin
Number of subjects: 100
Study 23483064 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 100
Study 23483064 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 100
Study 20974077 — intervention group
Group type: EXPERIMENTAL
Intervention: Online health intervention
Number of subjects: 0
Study 18981044 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled L-methamphetamine (16 microg)
Number of subjects: 12
Study 18981044 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled L-methamphetamine (48 microg)
Number of subjects: 12
Study 18981044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16684019 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D device
Number of subjects: 501
Study 16684019 — intervention group
Group type: EXPERIMENTAL
Intervention: History of spontaneous, sustained ventricular arrhythmia
Number of subjects: 501
Study 16684019 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class IV CHF
Number of subjects: 501
Study 16684019 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class II CHF excluded from analysis
Number of subjects: 501
Study 16684019 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D device in patients with NYHA class IV CHF
Number of subjects: 501
Study 12716688 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 50, 100, 200, 400, 600, or 800 micro g daily for 12 weeks
Number of subjects: 316
Study 12716688 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (estimated adequate dose) 392 micro g daily
Number of subjects: 316
Study 12716688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 10939175 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Coping Strategy Program (CCSP)
Number of subjects: 110